公开(公告)号：US20150182549A1

公开(公告)日：2015-07-02

申请号：US14408495

申请日：2013-06-24

申请人： Glycom A/S

发明人： Elise Champion ,  Dóra Molnár-Gábor ,  Gyula Dekany

IPC分类号： A61K31/715 ,  A23L1/30 ,  A23L1/29

CPC分类号： A61K31/715 ,  A23L29/275 ,  A23L33/10 ,  A23L33/40 ,  A23V2002/00 ,  C07H1/00 ,  C07H9/06 ,  C07H13/04 ,  C12P19/00 ,  C12P19/18 ,  C12P19/26 ,  C12Y302/01038 ,  C12Y302/01051 ,  A23V2200/304 ,  A23V2200/3202 ,  A23V2200/324 ,  A23V2250/28

摘要： A method for modifying galactosyl disaccharides in order to enhance their bifidogenic effect, comprising reacting at least one glycosyl donor with a precursor galactosyl disaccharide or a mixture of precursor galactosyl disaccharides using enzyme catalysis, compounds obtainable by said method and the use of such compounds in consumable products.

摘要翻译： 一种用于改善半乳糖二糖以增强其双发效应的方法，包括使用酶催化使至少一种糖基供体与前体半乳糖二糖或前体半乳糖二糖的混合物反应，可通过所述方法获得的化合物和这些化合物在消耗品中的用途 产品。

公开(公告)号：US08802841B2

公开(公告)日：2014-08-12

申请号：US12741973

申请日：2008-11-03

申请人： Gyula Dekany ,  István Bajza ,  Marie Bøjstrup ,  Károly Ágoston ,  Lars Kröger ,  Ignacio Figueroa Pérez ,  Christoph H. Röhrig ,  Paulo Vital ,  Erzsébet Czinege

发明人： Gyula Dekany ,  István Bajza ,  Marie Bøjstrup ,  Károly Ágoston ,  Lars Kröger ,  Ignacio Figueroa Pérez ,  Christoph H. Röhrig ,  Paulo Vital ,  Erzsébet Czinege

IPC分类号： A61K31/7016 ,  C07H5/06 ,  C07H15/12 ,  C07H15/16 ,  C07H15/203 ,  C08B37/00

CPC分类号： C07H15/12 ,  C07H5/06 ,  C07H15/203

摘要： A 1,2-dideoxy-1,2-diamino oligosaccharide or polysaccharide in its free base, salt or metal-complex form as shown in General Formula 1 and derivative thereof is described. R1, R2 and R3 are each independently selected from the group consisting of H and a carbohydrate moiety, with the proviso that at least one of the groups R1, R2 or R3 is a carbohydrate moiety; R4 is selected from the group consisting of: H, optionally substituted C1-20-alkyl, optionally substituted heteroalkyl, optionally substituted C2-20-alkenyl, optionally substituted C2-20-alkynyl, optionally substituted C3-10-cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.

摘要翻译： 描述了其通式1及其衍生物所示的其游离碱，盐或金属络合物形式的1,2-二脱氧-1,2-二氨基寡糖或多糖。 R 1，R 2和R 3各自独立地选自H和碳水化合物部分，条件是基团R 1，R 2或R 3中的至少一个是碳水化合物部分; R 4选自：H，任选取代的C 1-20 - 烷基，任选取代的杂烷基，任选取代的C 2-20 - 烯基，任选取代的C 2-20 - 炔基，任选取代的C 3-10 - 环烷基，任选取代的杂环基 ，任选取代的芳基和任选取代的杂芳基。

公开(公告)号：US20130072675A1

公开(公告)日：2013-03-21

申请号：US13698430

申请日：2011-05-19

申请人： Julien Boutet ,  Gyula Dekany ,  Ágnes Jánosi ,  Gergely Pipa ,  Ferenc Horváth ,  Krisztián Kovács ,  Ignacio Pérez Figueroa ,  Markus Hederos ,  Andreas Schroven ,  Ioannis Vrasidas ,  Piroska Kovács-Pénzes ,  Christian Risinger ,  Sándor Demkó ,  Lars Kröger ,  Christoph Röhrig

发明人： Julien Boutet ,  Gyula Dekany ,  Ágnes Jánosi ,  Gergely Pipa ,  Ferenc Horváth ,  Krisztián Kovács ,  Ignacio Pérez Figueroa ,  Markus Hederos ,  Andreas Schroven ,  Ioannis Vrasidas ,  Piroska Kovács-Pénzes ,  Christian Risinger ,  Sándor Demkó ,  Lars Kröger ,  Christoph Röhrig

IPC分类号： C07H1/06

CPC分类号： C07H3/02 ,  C07H1/06 ,  C07H3/08

摘要： The present application discloses a method for the crystallization of fucose, characterized in that the crystallization is carried out from a mixture comprising fucose and at least one 6-deoxy sugar selected from 6-deoxy-talose and 6-deoxy-gulose. In one embodiment, the mixture comprises fucose and 6-deoxy-talose.

摘要翻译： 本申请公开了一种岩藻糖结晶方法，其特征在于从包含岩藻糖和至少一种选自6-脱氧 - 托洛糖和6-脱氧 - 古洛糖的6-脱氧糖的混合物中进行结晶。 在一个实施方案中，混合物包含岩藻糖和6-脱氧 - 托洛糖。

公开(公告)号：US20110166339A1

公开(公告)日：2011-07-07

申请号：US13054314

申请日：2009-07-15

申请人： Gyula Dekany ,  Karoly Agoston ,  Istvan Bajza ,  Marie Bøjstrup ,  Ignacio Fegueroa Pérez ,  Lars Kröger ,  Christoph H. Röhrig

发明人： Gyula Dekany ,  Karoly Agoston ,  Istvan Bajza ,  Marie Bøjstrup ,  Ignacio Fegueroa Pérez ,  Lars Kröger ,  Christoph H. Röhrig

IPC分类号： C07H5/06

CPC分类号： C07H5/06 ,  C07H1/00

摘要： α-Lactosamine hydrochloride, substantially free of β-lactosamine hydrochloride; a method of preparing α-lactosamine hydrochloride monohydrate from an anomeric mixture of lactosamine hydrochloride, including: preparing a solution including the anomeric mixture of lactosamine hydrochloride, water and at least one water-miscible organic solvent at a temperature of 0-100° C., and cooling the solution to cause crystallisation of α-lactosamine hydrochloride monohydrate; a method of preparing anhydrous α-lactosamine hydrochloride; and use of α-lactosamine hydrochloride as a food supplement or intermediate in synthesis.

摘要翻译： α-乳糖胺盐酸盐，基本上不含β-乳糖胺盐酸盐; 一种从乳糖胺盐酸盐的端基异构体混合物制备α-乳糖胺盐酸盐一水合物的方法，包括：在0-100℃的温度下制备包括乳糖胺盐酸盐，水和至少一种水混溶性有机溶剂的端基异构体混合物的溶液 ，并冷却该溶液以引起α-乳糖胺盐酸盐一水合物的结晶; 制备无水α-乳糖胺盐酸盐的方法; 并使用盐酸α-乳糖胺作为食品添加剂或中间体。

公开(公告)号：US11684630B2

公开(公告)日：2023-06-27

申请号：US17099306

申请日：2020-11-16

申请人： GLYCOM A/S

发明人： Bruce McConnell ,  Emma Elison ,  Louise Kristine Vigsnæs

IPC分类号： A61K31/702 ,  A61P25/22 ,  A61P25/24 ,  A61P1/00 ,  C07H3/06 ,  A23L33/15

CPC分类号： A61K31/702 ,  A23L33/15 ,  A61P1/00 ,  A61P25/22 ,  A61P25/24 ,  C07H3/06 ,  A61K31/702 ,  A61K2300/00

摘要： A synthetic composition for use in improving one or more co-morbid mental disorder symptoms of a patient with IBS, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.

公开(公告)号：US20230133446A1

公开(公告)日：2023-05-04

申请号：US17906701

申请日：2021-01-29

申请人： GLYCOM A/S

发明人： Pierre CHASSAGNE

IPC分类号： A23C9/20 ,  C07H3/06 ,  C12P19/18 ,  F26B5/12 ,  F26B15/18 ,  A23C1/03 ,  A23L33/125 ,  A23L3/48 ,  A23P10/22 ,  A23L33/00 ,  A23C9/146 ,  A23C9/142

摘要： Various methods are provided for providing a solid HMO product, said methods including drum-drying, belt drying, preferably vacuum bed drying, or granulation. Solid HMO products are obtained via said methods, as well as solid HMO products per se. The methods can provide solid HMO products which are different to those achieved via other methods.

公开(公告)号：US20230114668A1

公开(公告)日：2023-04-13

申请号：US17906131

申请日：2021-03-12

申请人： Glycom A/S

发明人： Getachew S. MOLLA ,  Pierre CHASSAGNE

IPC分类号： C07H3/06 ,  C07H1/06 ,  C13B30/02

摘要： The invention relates to a method for selective crystallization of 2′-FL from an aqueous solution comprising 2′-FL and one or more other fucosylated carbohydrates by adding acetic acid to the solution.

公开(公告)号：US20230000886A1

公开(公告)日：2023-01-05

申请号：US17780869

申请日：2020-11-27

申请人： Glycom A/S

发明人： Louise Kristine Vigsnæs ,  Bruce McConnell ,  Dorthe Seitzberg ,  Ingvild Dybdrodt Amundsen

IPC分类号： A61K31/702 ,  A61P1/12

摘要： The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for prophylactically reducing gastrointestinal IBS symptom severity and/or symptom occurrence in a lac-tose-intolerant, IBS patient; reintroducing a source of lactose into the diet of a lactose-intolerant, IBS patient while prophylactically reducing gastrointestinal IBS symptom severity and/or symptom occurrence in the IBS patient; and/or reducing the severity and/or occurrence of non-gastrointestinal symptoms in a lactose-intolerant, IBS patient.

公开(公告)号：US11529365B2

公开(公告)日：2022-12-20

申请号：US17114850

申请日：2020-12-08

申请人： Glycom A/S

发明人： Bruce McConnell ,  Louise Kristine Vigsnæs

IPC分类号： A61K31/702 ,  A61K45/06 ,  A61P31/00 ,  A61P3/10 ,  A61P29/00 ,  A61K35/20 ,  A61K35/00

摘要： A method and composition including an effective amount of one or more synthetic neutral HMOs are disclosed for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation and for improving one or more gastrointestinal conditions.

公开(公告)号：US11529364B2

公开(公告)日：2022-12-20

申请号：US17093337

申请日：2020-11-09

申请人： GLYCOM A/S

发明人： Emma Elison ,  Bruce McConnell ,  Thierry Hennet ,  Louise Kristine Vigsnæs

IPC分类号： A61K31/702 ,  A61K31/7012 ,  A61K31/7004 ,  A61K9/00

摘要： A method for treating metabolic disorders in non-infant includes administering to an obese non-infant human during a treatment period an effective amount of a mixture of two or more synthetic neutral human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), and lacto-N-neotetraose (LNnT), and optionally one or more excipients. The method further includes increasing in the gastrointestinal microbiota of the non-infant human during the treatment period, the relative abundance of Bifidobacterium adolescentis and reducing in the non-infant human during the treatment period, a precursor condition for a metabolic disorder associated with development of one or more of obesity-induced pre-diabetes and type 2 diabetes, the precursor condition selected from gut permeability, metabolic endotoxemia, low-grade metabolic inflammation, and body fat percentage.